Niacin shows lower-than-expected risk for new-onset diabetes

03/7/2012 | Medscape (free registration)

A study of 942 patients with hyperlipemia showed the frequency of new-onset diabetes in those who took ezetimibe/simvastatin plus extended-release niacin was 3.5% at 64 weeks, a rate only "marginally higher" than 2.6% in those who had ezetimibe/simvastatin-only treatment. The findings appear in Diabetes Care.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC